NICE confirms Jetrea recommendation for VMT

Jetrea web 2 NICE has issued final guidance recommending Jetrea (ocriplasmin) for treatment of the sight-threatening disorder vitreomacular traction (VMT).

The recommendation confirms the earlier draft guidance and replaces local NHS recommendations, ensuring the ThromboGenics drug will be available nationally.

Jetrea is a form of human plasmin manufactured using recombinant DNA technology; its uptake by the NHS reflects the growing clinical success of biological therapies based on genetic research.

The drug is recommended for use in adults who do not have an epiretinal membrane (a complication of VMT) but who have a stage II macular hole (with a diameter up to 400µm) and/or severe symptoms.

VMT occurs when the gel in the eyeball pulls on the retina, causing distortion of vision and potentially a hole in the macular area responsible for central vision.

Administered by intravitreal injection, Jetrea has a lasting effect on retinal cells: no repeat injections are needed.

Professor Carole Longson, Director of NICE’s Health Technology Evaluation Centre, said: “Vitreomacular traction is a serious eye condition, which can lead to loss of vision in the long run. Ocriplasmin injection represents a new and welcome option for patients with this condition and their clinicians, as it provides an alternative to ‘watch and wait’ and/or surgery.”